Option Care Health (NASDAQ:OPCH) Price Target Lowered to $34.00 at Truist Financial

Option Care Health (NASDAQ:OPCH) had its price objective decreased by investment analysts at Truist Financial from $41.00 to $34.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 47.57% from the stock’s previous close.

A number of other brokerages have also recently commented on OPCH. JMP Securities raised their target price on Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a report on Monday, September 30th. Bank of America downgraded shares of Option Care Health from a “buy” rating to a “neutral” rating and reduced their price target for the company from $43.00 to $29.00 in a report on Wednesday. Jefferies Financial Group downgraded Option Care Health from a “buy” rating to a “hold” rating and lowered their target price for the company from $38.00 to $26.00 in a research report on Thursday. Finally, Barrington Research reduced their price objective on Option Care Health from $40.00 to $32.00 and set an “outperform” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Option Care Health has a consensus rating of “Moderate Buy” and an average price target of $31.60.

Option Care Health Price Performance

OPCH stock opened at $23.04 on Friday. The company has a market cap of $3.94 billion, a P/E ratio of 19.36, a PEG ratio of 1.79 and a beta of 1.29. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.36. The firm has a 50-day moving average of $30.65 and a 200 day moving average of $29.97. Option Care Health has a 1 year low of $22.84 and a 1 year high of $34.63.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.31 by $0.05. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.22 billion. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. On average, sell-side analysts forecast that Option Care Health will post 1.22 EPS for the current year.

Insider Transactions at Option Care Health

In other Option Care Health news, CFO Michael H. Shapiro sold 23,217 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total transaction of $718,566.15. Following the transaction, the chief financial officer now owns 247,317 shares of the company’s stock, valued at approximately $7,654,461.15. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Michael H. Shapiro sold 23,217 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.95, for a total transaction of $718,566.15. Following the transaction, the chief financial officer now owns 247,317 shares of the company’s stock, valued at approximately $7,654,461.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elizabeth Quadros Betten sold 47,531 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the sale, the director now owns 21,339 shares in the company, valued at approximately $663,429.51. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OPCH. Massachusetts Financial Services Co. MA purchased a new position in Option Care Health during the 2nd quarter worth $68,003,000. Magnetar Financial LLC raised its position in shares of Option Care Health by 124.8% in the second quarter. Magnetar Financial LLC now owns 2,481,935 shares of the company’s stock valued at $68,750,000 after buying an additional 1,377,929 shares during the last quarter. Duquesne Family Office LLC boosted its holdings in shares of Option Care Health by 172.8% during the second quarter. Duquesne Family Office LLC now owns 1,871,818 shares of the company’s stock worth $51,849,000 after purchasing an additional 1,185,613 shares during the last quarter. Hood River Capital Management LLC grew its holdings in Option Care Health by 77.2% in the 2nd quarter. Hood River Capital Management LLC now owns 1,729,029 shares of the company’s stock valued at $47,894,000 after buying an additional 753,208 shares during the period. Finally, Westfield Capital Management Co. LP increased its position in Option Care Health by 15.4% during the first quarter. Westfield Capital Management Co. LP now owns 5,171,385 shares of the company’s stock worth $173,448,000 after purchasing an additional 688,653 shares during the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.